PIEZO1 and sickle cell disease: The effects of Yoda1, a pharmacological activator of PIEZO1, were investigated on intracellular [Ca2+] ([Ca2+]i) and phosphatidylserine (PS) exposure in red cells from patients with sickle cell anaemia (SCA).